MyoKardia, Inc. said that the FDA has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
- company is currently preparing an NDA for mavacamten, with plans to submit to the FDA in the 1Q 2021
- Shares rose 1.8% in post-market trading
To view the source of this information click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2020 Bloomberg L.P. All rights reserved. Used with permission. ...